RayKnowChina Research Map
Shortlist0

RecruitingOesophageal squamous cell carcinomaPhase 2

Registered title, quoted from ClinicalTrials.gov

A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC

An open trial on oesophageal squamous cell carcinoma, registered on ClinicalTrials.gov. Led by Zhejiang Cancer Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorZhejiang Cancer Hospital浙江省肿瘤医院HangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06190639, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 8

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (8 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Histologically confirmed T1-3N+M0 thoracic esophageal squamous cell cancer (AJCC 8th)

    Inclusion criterion 4

  3. Glucocorticoids are required for 14 days prior to treatment (daily>10 mg equivalent dose of prednisone) or other immunosuppressive drugs for systemic treatment.

    Exclusion criterion 8

    Participants were found to have active hepatitis B (Hepatitis B surface antigen [HBsAg] positive or hepatitis C virus (HCV) positive (HCV RNA positive) Sex). Participants with prior HBV infection or recovered HBV infection (defined as having hepatitis B core antibodies [HBcAb] and no HBsAg) were eligible. HBV DNA must be obtained from these patients before treatment. Participants who are HBV carriers or require antiviral therapy are not eligible to participate. Participants who were positive for HCV antibodies were eligible only if the PCR for HCV RNA was negative.

    Exclusion criterion 16

  4. ECOG PS 0-1

    Inclusion criterion 3

  5. WBC ≥2000/μL;

    Inclusion criterion 9

    Neutrophils ≥1500/μL;

    Inclusion criterion 10

    Platelets ≥100 x 103/μL;

    Inclusion criterion 11

    Hemoglobin ≥9.0 g/dL;

    Inclusion criterion 12

    Creatinine: Serum creatinine ≤1.5 x above normal (ULN) or creatinine removal rate > 50mL/ min (Cockcroft/Gault formula);

    Inclusion criterion 13

    AST ≤3 x ULN;

    Inclusion criterion 14

    ALT ≤3 x ULN;

    Inclusion criterion 15

    Total bilirubin ≤1.5 x ULN (except for subjects with Gilbert syndrome, where total bilirubin must be < 3 x ULN);

    Inclusion criterion 16

  6. All participants must be confirmed disease-free by physical and imaging examinations within 4 weeks prior to enrollment. Imaging examinations must include CT/MRI scans of the neck, chest and abdomen.

    Inclusion criterion 7

  7. A known history of testing positive for human immunodeficiency virus (HIV) or a known history of acquired immunodeficiency syndrome (AIDS)

    Exclusion criterion 9

    Active malignancy within the last 3 years, other than locally curable cancers that have apparently been cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.

    Exclusion criterion 13

  8. Women of child bearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity of HCG is 25 IU/L or equivalent) within 24 hours before starting study treatment.

    Inclusion criterion 19

    Women must be non-breastfeeding

    Inclusion criterion 20

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06190639, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Signed an Informed Consent Form
  • Participant type and target disease characteristics:
  • ECOG PS 0-1
  • Histologically confirmed T1-3N+M0 thoracic esophageal squamous cell cancer (AJCC 8th)
  • can tolerate radical resection of esophageal cancer
  • Resection must be performed within 4-12 weeks prior to enrollment
  • All participants must be confirmed disease-free by physical and imaging examinations within 4 weeks prior to enrollment. Imaging examinations must include CT/MRI scans of the neck, chest and abdomen.
  • All baseline laboratory tests will be evaluated as required and results should be available within 28 days prior to enrollment. Laboratory test values must be selected according to the following criteria (CTCAE V5.0):
  • WBC ≥2000/μL;
  • Neutrophils ≥1500/μL;
  • Platelets ≥100 x 103/μL;
  • Hemoglobin ≥9.0 g/dL;
  • Creatinine: Serum creatinine ≤1.5 x above normal (ULN) or creatinine removal rate > 50mL/ min (Cockcroft/Gault formula);
  • AST ≤3 x ULN;
  • ALT ≤3 x ULN;
  • Total bilirubin ≤1.5 x ULN (except for subjects with Gilbert syndrome, where total bilirubin must be < 3 x ULN);
  • Age and fertility status:
  • Age ≥18 years old
  • Women of child bearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity of HCG is 25 IU/L or equivalent) within 24 hours before starting study treatment.
  • Women must be non-breastfeeding

Exclusion Criteria:

  • Target disease
  • The presence of locally advanced unresectable (regardless of stage) or metastatic disease.
  • Cervical and abdominal esophageal tumors.
  • Medical history and concurrent diseases
  • Complete resection followed by treatment for the removed esophageal cancer (e.g., chemotherapy, targeted drugs, radiation, or biotherapy).
  • Participants with ≥ grade 2 peripheral neuropathy
  • Participants with active, known, or suspected autoimmune diseases. Participants with type I diabetes, hypothyroidism requiring only hormone replacement therapy, skin conditions that do not require systemic treatment (such as vitiligo, psoriasis, or hair loss), or conditions that are not expected to recur without external irritants, may be enrolled.
  • Glucocorticoids are required for 14 days prior to treatment (daily>10 mg equivalent dose of prednisone) or other immunosuppressive drugs for systemic treatment.

If there is no active autoimmune disease, inhaled or topical steroid hormones are permitted, and daily>10 mg prednisone equivalent dose of adrenal hormone replacement therapy.

  • A known history of testing positive for human immunodeficiency virus (HIV) or a known history of acquired immunodeficiency syndrome (AIDS)
  • Participants with a serious or uncontrolled medical condition.
  • Radiotherapy, chemotherapy, immunotherapy, esophagectomy, esophagus-gastric junction, and gastric surgery were performed before the trial.
  • Participants with severe cardiovascular or pulmonary disease, interstitial pneumonia, or a history of prior interstitial pneumonia.
  • Active malignancy within the last 3 years, other than locally curable cancers that have apparently been cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.
  • Participants with a serious or uncontrolled medical condition
  • Physical and laboratory examination
  • Participants were found to have active hepatitis B (Hepatitis B surface antigen [HBsAg] positive or hepatitis C virus (HCV) positive (HCV RNA positive) Sex). Participants with prior HBV infection or recovered HBV infection (defined as having hepatitis B core antibodies [HBcAb] and no HBsAg) were eligible. HBV DNA must be obtained from these patients before treatment. Participants who are HBV carriers or require antiviral therapy are not eligible to participate. Participants who were positive for HCV antibodies were eligible only if the PCR for HCV RNA was negative.
  • Allergies and adverse drug reactions
  • History of allergy or hypersensitivity to study drug ingredients.
  • A history of severe hypersensitivity to any monoclonal antibody.
  • Other exclusion criteria
  • Participants who do not understand or may not comply with the requirements of the trial
  • Participants had an active infection requiring systemic treatment in the 28 days prior to first dosing
  • Some obvious diseases that the researchers believe should be excluded from this study

Quoted from ClinicalTrials.gov, NCT06190639, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06190639, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06190639